Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509883 | 0.82 | TDP1 (0.38) | CTRCHTTOPRK1ALDH1A1GAA | |
| SCHEMBL12155066 | 0.82 | HTT (0.39) | CTRCHTTALDH1A1GAA | |
| SCHEMBL509731 | 0.82 | PNMT (0.41) | CTRC | |
| SCHEMBL15177155 | 0.79 | KDM4E (0.40) | CTRCCA2OPRK1ALDH1A1GAA | |
| SCHEMBL510432 | 0.79 | HSD17B10 (0.48) | CTRCHTTALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL282247 | 0.77 | — | — | |
| SCHEMBL510332 | 0.73 | CTBP2 (0.36) | CTRCHTT | |
| SCHEMBL510259 | 0.72 | CTRC (0.34) | CTRCOPRK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8992968 | 0.72 | IDO1 (0.48) | CA1CA2HSP90AB1ALDH1A1 | |
| SCHEMBL11323181 | 0.71 | CYP3A4 (0.47) | CA1CA2HTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183264-B2 | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same | Eisai R&D Managment Co., Ltd. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183264-B2 | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same | Eisai R&D Managment Co., Ltd. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183264-B2 | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same | Eisai R&D Managment Co., Ltd. (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-2065377-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2065377-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | ERG28, CBR3, CBR1 | CTRC 883/4885CA1 3135/4885CA2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.